idiopath
inflammatori
myopathi
encompass
heterogen
group
system
autoimmun
diseas
includ
polymyos
pm
character
symmetr
proxim
progress
muscl
weak
limb
dermatomyos
dm
addit
muscl
involv
includ
skin
abnorm
heliotrop
gottron
papul
viral
infect
herp
zoster
hz
increasingli
report
individu
system
autoimmun
diseas
among
patient
system
lupu
erythematosu
instanc
hz
preval
incid
patientyear
corticosteroid
immunosuppress
agent
diseas
activ
presenc
antism
autoantibodi
number
among
possibl
risk
factor
hz
popul
incid
hz
rheumatoid
arthriti
patientyear
risk
factor
cohort
includ
older
age
year
old
presenc
cancer
chronic
lung
diseas
corticosteroid
usag
exposur
immunosuppress
immunobiolog
therapi
immun
system
dysregul
epidemiolog
studi
hz
dmpm
investig
within
context
opportunist
infect
examin
myositi
case
hz
thu
fardet
et
al
analyz
incid
risk
factor
sever
hz
patient
dm
howev
author
evalu
hz
herp
simplex
dm
patient
without
malign
mari
et
al
assess
sever
opportunist
sever
infect
patient
dmpm
period
year
found
three
case
hz
nagaoka
et
al
analyz
incid
hz
patient
dmpm
period
year
five
patient
histori
viral
infect
predominantli
occur
remiss
stage
diseas
show
relationship
drug
therapi
due
dearth
public
topic
aim
studi
analyz
preval
risk
factor
outcom
hz
cohort
dmpm
patient
januari
januari
consecut
patient
dm
pm
fulfil
least
four
five
bohan
peter
criteria
follow
tertiari
hospit
twentyfour
subject
group
histori
hz
remain
patient
without
hz
control
group
patient
two
control
everi
hz
patient
form
match
gender
diseas
type
dm
pm
age
onset
myositi
diseas
durat
studi
approv
local
research
ethic
committe
demograph
drug
therapi
clinic
laboratori
data
retrospect
obtain
systemat
review
patient
medic
record
drug
therapi
laboratori
data
base
time
dmpm
diagnosi
season
hz
event
occur
clinic
manifest
consid
present
followup
patient
constitut
symptom
skin
chang
eg
heliotrop
gottron
papul
ulcer
photosensit
calcinosi
vascul
joint
involv
arthralgia
andor
arthriti
gastrointestin
dysphagia
respiratori
dyspnea
moder
exert
manifest
analyz
creatin
kinas
normal
rang
iul
aldolas
iul
determin
use
autom
kinet
assay
leukocyt
count
lactat
dehydrogenas
alanin
aminotransferas
aspart
aminotransferas
also
assess
erythrocyt
sediment
rate
creactiv
protein
level
evalu
use
westergren
nephelometri
method
respect
autoantibodi
cellular
compon
determin
indirect
immunofluoresc
use
cell
substrat
autoantibodi
determin
use
western
blot
method
patient
first
start
corticosteroid
prednison
mgkgday
administ
oral
taper
gradual
accord
clinic
laboratori
stabil
case
high
diseas
sever
dysphagia
risk
aspir
pneumonia
cutan
vascul
refractori
oral
corticosteroid
intraven
corticosteroid
administ
methyl
prednisolon
gday
three
consecut
day
follow
drug
use
alon
combin
corticosteroid
spare
azathioprin
mgkgday
methotrex
mgweek
cyclosporin
mgkgday
mycophenol
mofetil
gday
leflunomid
mgday
cyclophosphamid
bodi
surfac
intraven
human
immunoglobulin
gkgday
two
consecut
day
chloroquin
diphosph
mgkgday
hz
infect
clinic
defin
appear
typic
vesicular
erupt
distribut
dermatom
potenti
complic
hz
list
protocol
form
includ
postherpet
neuralgia
persist
pain
one
month
disappear
rash
cutan
dissemin
vesicular
lesion
outsid
primari
adjac
dermatom
lesion
initi
evalu
rheumatologist
dermatologist
servic
diseas
statu
time
hz
diagnosi
defin
partial
clinic
respons
evid
diseas
activ
within
last
month
diseas
b
complet
clinic
respons
continu
period
evid
diseas
activ
still
receiv
myositi
therapi
c
clinic
remiss
continu
period
evid
diseas
activ
myositi
therapi
diseas
activ
defin
increas
muscl
enzym
sera
level
clinic
evid
limb
muscl
weak
two
consecut
medic
evalu
continu
variabl
express
deviat
sd
median
interquartil
rang
iqr
percentag
categor
variabl
student
ttest
mannwhitney
utest
continu
variabl
employ
evalu
differ
dmpm
group
confid
interv
ci
calcul
use
binomi
distribut
variabl
significantli
differ
statist
univari
analysi
comparison
patient
without
hz
episod
without
neurolog
sequela
select
adjust
sex
ageadjust
odd
ratio
or
ci
calcul
use
uncondit
logist
model
p
consid
statist
signific
followup
period
patient
hz
dm
case
pm
case
twothird
femal
clinic
demograph
featur
patient
shown
tabl
gener
characterist
compar
group
without
hz
except
higher
preval
dm
group
hz
compar
patient
without
hz
p
mean
age
patient
hz
year
rang
year
demograph
clinic
variabl
patient
hz
group
compar
randomli
select
match
patient
without
hz
shown
tabl
differ
detect
two
group
regard
cumul
clinic
manifest
tabl
furthermor
two
group
compar
term
current
diseas
statu
laboratori
paramet
initi
current
autoantibodi
tabl
hz
patient
initi
receiv
intraven
acyclovir
mgkgday
differ
dmpm
without
hz
regard
glucocorticoid
therapi
current
use
medium
dose
cumul
dose
two
previou
month
similarli
immunosuppress
therapi
use
similar
group
tabl
howev
patient
use
chloroquin
diphosph
ci
greater
risk
develop
hz
compar
patient
receiv
chloroquin
diphosph
treatment
tabl
show
dermatom
locat
hz
well
clinic
evalu
six
case
simultan
involv
two
dermatom
neurolog
sequela
occur
patient
case
hz
recurr
report
durat
neurolog
symptom
year
demograph
diseas
statu
clinic
laboratori
featur
compar
patient
without
postherpet
neuralgia
howev
latter
group
use
higher
prednison
dose
time
hz
diagnosi
median
mgday
rang
former
group
median
mgday
rang
p
ci
present
studi
identifi
chloroquin
diphosph
primari
risk
factor
hz
dmpm
popul
note
high
hz
preval
predominantli
affect
women
individu
dm
import
aspect
retrospect
studi
design
larg
cohort
hz
case
associ
risk
factor
patient
dm
pm
consid
rare
system
autoimmun
diseas
addit
studi
control
group
match
age
known
hz
cluster
dispar
young
elderli
subject
moreov
gender
diseas
type
dm
pm
age
diagnosi
diseas
durat
also
control
sampl
match
avoid
confound
bia
despit
enrol
larg
sampl
mani
author
found
hz
case
dmpm
popul
notabl
mari
et
al
identifi
three
individu
hz
case
yu
et
al
detect
two
subject
hz
among
case
dmpm
wherea
fardet
et
al
found
hz
case
among
dm
patient
present
studi
evalu
hz
case
among
patient
clinic
diagnos
dmpm
followup
period
therefor
consider
number
infect
patient
identifi
popul
base
system
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
arthriti
major
risk
factor
develop
hz
includ
older
age
use
corticosteroid
immunosuppress
agent
diseas
activ
femal
sex
cancer
lung
diseas
impair
cellular
immun
popul
hz
predominantli
affect
adult
mean
age
year
rang
year
tendenc
toward
affect
older
individu
moreov
avoid
analysi
bia
individu
neoplasia
exclud
contrast
system
autoimmun
diseas
impair
cellular
immun
consid
risk
factor
hz
develop
humor
immun
function
might
consid
relev
inflammatori
myopathi
preval
hz
higher
dm
patient
compar
pm
patient
immunopatholog
standpoint
lymphocyt
macrophag
infiltr
primarili
found
pm
muscl
fiber
wherea
dm
b
cell
play
import
role
pathogenesi
diseas
presenc
autoantibodi
immun
complex
deposit
dermoepiderm
junction
skin
lesion
presenc
b
cell
inflam
muscl
perivascular
area
addit
deposit
complement
immunoglobulin
perifascicular
endothelium
lead
ischemia
muscl
atrophi
underlin
import
humor
immun
thu
disturb
humor
immun
might
increas
hz
reactiv
found
higher
preval
hz
dm
patient
compar
pm
patient
nagaoka
et
al
analyz
five
hz
case
among
dmpm
patient
note
infect
affect
patient
without
diseas
activ
found
correl
time
corticosteroid
use
result
show
hz
preval
independ
diseas
statu
clinic
laboratori
featur
includ
cutan
manifest
moreov
daili
andor
cumul
dosag
corticosteroid
andor
intraven
puls
methylprednisolon
increas
risk
hz
develop
popul
likewis
use
immunosuppress
therapi
methotrex
azathioprin
mycophenol
mofetil
leflunomid
cyclophosphamid
alon
associ
hz
howev
patient
use
chloroquin
diphosph
fivefold
greater
risk
develop
hz
compar
patient
receiv
chloroquin
diphosph
treatment
chloroquin
diphosph
analogu
hydroxychloroquin
use
treat
variou
rheumat
diseas
rheumatoid
arthriti
system
lupu
erythematosu
sarcoidosi
dermatomyos
syndrom
chronic
juvenil
arthriti
psoriat
arthriti
drug
offer
clinic
benefit
accept
safeti
profil
drug
also
use
treat
inflammatori
myopathi
particularli
cutan
symptom
dm
chloroquin
might
also
antivir
activ
lysosomotrop
weak
base
impair
replic
virus
reduc
effici
endosomemedi
viru
entri
inhibit
proteas
transgolgi
vesicl
antivir
activ
human
immunodefici
viru
sar
coronaviru
also
demonstr
howev
chloroquin
also
shown
increas
symptom
sever
mortal
eg
follow
semliki
forest
viru
encephalomyocard
viru
infect
well
increas
viral
titer
variou
organ
result
clearli
show
chloroquin
risk
factor
hz
develop
subject
dmpm
independ
diseas
statu
therapi
demograph
featur
regard
clinic
evalu
least
half
patient
neurolog
sequela
six
patient
simultan
involv
two
dermatom
case
hz
recurr
report
postherpet
neuralgia
result
sever
pain
patient
often
unabl
wear
cloth
come
contact
lesion
expos
wind
high
skin
sensit
region
thorax
face
incid
postherpet
neuralgia
rise
among
individu
age
high
among
age
year
older
larg
prospect
studi
identifi
four
independ
predictor
postherpet
neuralgia
older
age
sever
acut
pain
sever
rash
shorter
durat
rash
consult
although
controversi
shortterm
use
corticosteroid
reduc
pain
sever
improv
patient
qualiti
life
acut
phase
note
high
prednison
dose
time
hz
diagnosi
found
decreas
incid
postherpet
neuralgia
patient
conclus
data
show
high
preval
hz
dmpm
popul
studi
confirm
chloroquin
diphosph
risk
factor
hz
develop
popul
particularli
women
dm
patient
research
necessari
evalu
possibl
molecular
mechan
underli
higher
hz
preval
dm
subject
compar
pm
patient
popul
studi
partial
support
federico
foundat
